5 recruiting, 3 completed, 1 not yet recruiting. 8 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 5, Completed 2, Not yet recruiting 1 |
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Completed 1 |
Follow Jecho Biopharmaceuticals Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg - Malignancies, Solid Malignant Tumor | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 14 | 2026-06-25 | 2026-08-11 |
| A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) JL15003Injection - Recurrent Glioblastoma Multiforme(GBM) | Phase 1 / Phase 2 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 40 | 2026-06-17 | 2026-08-10 |
| Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders JL18008 - HIV | Phase 1 | Not yet recruiting | Jecho Biopharmaceuticals Co., Ltd. | 52 | 2026-05-30 | 2026-03-02 |
| A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders JL18008 20 μg/kg, Placebo (for 20 μg/kg Group), JL18008 40 μg/kg - HIV Infections | Phase 1 / Phase 2 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 30 | 2026-05-26 | 2026-08-06 |
| A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer. JL19001 Injection - High Risk Non-muscle Invasive Bladder Cancer | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 18 | 2026-05-18 | 2026-08-06 |
| A Phase I Study of JLM019 Injection JLM019 Injection - Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 115 | 2026-01-13 | 2026-06-03 |
| To Evaluate the Safety of JL18008 JL18008 1 μg/kg, JL18008 5 μg/kg, JL18008 10 μg/kg - HIV Infections | Phase 1 | Completed | Jecho Biopharmaceuticals Co., Ltd. | 40 | 2024-06-13 | 2026-06-11 |
| A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma JL15003 Injection - Recurrent Glioblastoma Multiforme(GBM) | Phase 1 | Completed | Jecho Biopharmaceuticals Co., Ltd. | 17 | 2022-11-16 | 2026-04-03 |
| A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) JL14002 monoclonal antibody(Fixed dosing regimen), Ranibizumab(Fixed dosing regimen), JL14002 monoclonal antibody(PRN) - Wet Age-related Macular Degeneration | Phase 3 | Completed | Jecho Biopharmaceuticals Co., Ltd. | 443 | 2022-03-01 | 2026-02-05 |
Glioblastoma (2) · HIV Infections (2) · Lymphoma, Non-Hodgkin (2) · Hodgkin Disease (1) · Neoplasms (1)
Population Groups (2) · WW Domain-Containing Oxidoreductase (2) · Injections (1) · Injections, Subcutaneous (1)
China (8)
Qiang Wei (1)